Business
Vor Announces AML Clinical Data + Raises $115M
Vor Announces AML Clinical Data + Raises $115M.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n 7\n \n December\n \n \n 2022\n \n \n \n PureTech Health plc\n \n \n \n \n \n \n \n PureTech Founded Entity Vor Bio Announces First AML Patient Successfully Transplanted with its Investigational Trem-cel (VOR33) and Tolerated Mylotarg™\n \n \n Trem-cel (formerly VOR33) successfully manufactured and engrafted normally\n \n \n Blood counts successfully maintained following post-transplant treatment with Mylotarg\n \n \n Vor Bio also announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million\n \n \n PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced initial clinical data from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of tremtelectogene empogeditemcel or \"trem-cel\" (formerly VOR33) in patients with acute myeloid leukemia (AML). The data observed from the first treated patient support the potential of a trem-cel transplant to be successfully manufactured, to engraft normally, and to maintain blood counts following treatment with the CD33-targeted therapy Mylotarg. The clinical trial continues to enroll patients and additional data are expected in 2023.\n Vor also separately announced today the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million. PureTech's percentage ownership of Vor Bio as at November 4, 2022 was approximately 8.2 percent on a beneficial ownership basis, prior to the transaction.\n \n The full text of the announcement from Vor is below:\n \n \n \n \n \n First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™\n \n \n ·\n Trem-cel (formerly VOR33) successfully manufactured and engrafted normally\n \n \n ·\n Blood counts successfully maintained following post-transplant treatment with Mylotarg\n \n \n ·\n Conference call scheduled for today, December 7 at 8:00am ET\n \n \n CAMBRIDGE, Mass., Dec. 07, 2022 -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced initial clinical data from VBP101, its...